No abstract

medians (70%, 95% CI 65-74%) than those in 2012 (50%, 95% CI 46-56%). There was a significant relationship between age and adherence, with older subjects having a higher median PDC (4% more for 10 years difference). Conclusions: A recent analysis suggests that drug levels consistent with ‡ 4 TVD pills/wk resulted in a HIV risk reduction of 86-100%. Overall adherence to TVD for PrEP in this retail data base population is consistent with levels that have shown significant reduction in HIV transmission in clinical trials. This is the first assessment of adherence to PrEP among individuals outside of a clinical trial setting. Novel Vaccine ConceptsOA16.01